A descriptive cost‐analysis of MYX.1/MCRN003, a phase 2 clinical trial evaluating high‐dose weekly carfilzomib, cyclophosphamide, and dexamethasone in relapsed and refractory multiple myeloma-Reference-Cited by-同舟云学术

A descriptive cost‐analysis of MYX.1/MCRN003, a phase 2 clinical trial evaluating high‐dose weekly carfilzomib, cyclophosphamide, and dexamethasone in relapsed and refractory multiple myeloma

Published:2021-06-23 Issue:3 Volume:107 Page:333-342
ISSN:0902-4441
Container-title:European Journal of Haematology
language:en
Short-container-title:Eur J Haematol

Author:

Monteith Bethany E.¹²^ORCID,Venner Christopher P.³,Cheung Matthew C.⁴,Pater Joe¹,Shepherd Lois¹,Richardson Harriet¹,Reece Donna⁵,Gul Engin⁶,Lalancette Marc⁷,Castonguay Vincent⁷,Kukreti Vishal⁵,Tiedemann Rodger⁵,Phua Chai⁸,Bhella Sita²,Dudebout Jill²,Sherry Max¹,Yen Hope¹,Chen Bingshu E.¹,Hay Annette E.¹²

Affiliation:

1. Canadian Cancer Trials Group Queen's University Kingston ON Canada

2. Cancer Center of Southeastern Ontario Queen's University Kingston ON Canada

3. The Cross Cancer Institute University of Alberta Edmonton AB Canada

4. Odette Cancer Centre University of Toronto Toronto ON Canada

5. Princess Margaret Cancer Centre University of Toronto Toronto ON Canada

6. Canadian Myeloma Research Group (formerly the Myeloma Canada Research Network) Vaughan ON Canada

7. CHU de Québec Hôtel‐Dieu de Québec Université Laval Quebec City QC Canada

8. Victoria Hospital Western University London ON Canada

Publisher

Wiley

Subject

Hematology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/ejh.13671

Reference38 articles.

1. Canadian Cancer Society.Canadian Cancer Statistics A 2020 special report on cancer incidence by stage;2020.

2. Weekly carfilzomib plus cyclophosphamide and dexamethasone in the treatment of relapsed/refractory multiple myeloma: Final results from the MCRN ‐003/ MYX .1 single arm phase II trial

3. Overall and Progression Free Survival from the Mcrn-003/Myx.1 Trial: A Single Arm Phase II Study of High-Dose Weekly Carfilzomib Plus Cyclophosphamide and Dexamethasone in the Treatment of Relapsed Multiple Myeloma

4. A single arm phase II study of high‐dose weekly carfilzomib plus cyclophosphamide and dexamethasone in the treatment of relapsed multiple myeloma after 1–3 Prior therapies;Venner C;Blood,2018

5. Phase-specific and lifetime costs of cancer care in Ontario, Canada